Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...

US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...

In addition to their role in the recognition of specific antigen through the BCR, B cells can transport antigen to FDCs, as illustrated by splenic marginal-zone B cells. These cells shuttle from ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...